Paratek's pneumonia data sends shares rocketing

4 April 2017

US biopharma Paratek Pharmaceuticals (Nasdaq: PRTK) was up around 35% at $18.60 during pre-market trading on Tuesday as investors reacted to news on its lead candidate, omadacycline.

This once-daily oral and IV, broad spectrum investigational antibiotic, met all US Food and Drug Administration (FDA) primary and secondary endpoints and European Medicines Agency (EMA) co-primary endpoints in a global, pivotal Phase III study in community-acquired bacterial pneumonia (CABP).

The trial is a comparison of Paratek’s drug to moxifloxacin and represents the second positive Phase III registration study of omadacycline, which was also shown to be generally safe and well tolerated, consistent with prior studies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK